3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer

Резултати

Title:	3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Authors:	Verschraegen, C; Andric, Zoran G ; Moiseenko, FV; Makharadze, T; Oleksiienko, A; Ruiz, EP Yanez; Kim, SH; Ahn, K; Park, TH; Ju, HA; Baek, EH; Kwon, S; Lee, SJ; Chang, I; Kim, SH; Kim, HA; Lee, E; Ohe, Y;
Issue Date:	2024
Publication:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Search Idenfier
Type:	Conference Paper
Collation:	vol. 35 str. S1648-S1649
DOI:	10.1016/j.annonc.2024.10.685
WoS-ID:	001401985200441
URI:	https://enauka.gov.rs/handle/123456789/970648
Project:	Celltrion Inc.
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

Алт метрика

Dimensions

Unpaywall

Google Scholar^TM

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.